Cover Image

Downstaging with atezolizumab-bevacizumab: a case series

Backgrounds/Aims Hepatocellular carcinoma (HCC) is generally diagnosed at an advanced stage, which limits curative treatment options for these patients. Locoregional therapy (LRT) is the standard approach to bridge and downstage unresectable HCC for liver transplantation (LT). Atezolizumab-bevacizum...

Full description

Saved in:

Bibliographic Details
Main Authors:	Anand V. Kulkarni (Author), Parthasarathy Kumaraswamy (Author), Balachandran Menon (Author), Anuradha Sekaran (Author), Anuhya Rambhatla (Author), Sowmya Iyengar (Author), Manasa Alla (Author), Shantan Venishetty (Author), Sumana Kolar Ramachandra (Author), Giri V. Premkumar (Author), Mithun Sharma (Author), P. Nagaraja Rao (Author), Duvvur Nageshwar Reddy (Author), Amit G. Singal (Author)
Format:	Book
Published:	Korean Liver Cancer Association, 2024-09-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Pustular psoriasis triggered by therapy with atezolizumab and bevacizumab
by: Mariani Magnus da Luz Andrade, et al.
Published: (2024)

Evaluation of cardiovascular toxicity of the atezolizumab and bevacizumab combination
by: Takahiro Niimura, et al.
Published: (2023)

A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
by: Yukinobu Watanabe MD, PhD, et al.
Published: (2021)

Atezolizumab plus bevacizumab and chemotherapy versus bevacizumab plus chemotherapy for metastatic cervical cancer: a cost-effectiveness analysis
by: Hongfu Cai, et al.
Published: (2024)

Comparison of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis
by: Jeayeon Park, et al.
Published: (2024)

Feasibility of additional radiotherapy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab
by: Tae Hyun Kim, et al.
Published: (2023)

Multidisciplinary approaches to downstaging hepatocellular carcinoma: present and future
by: Sang-Youn Hwang, et al.
Published: (2024)

Atezolizumab Plus Bevacizumab-induced Recalcitrant Pyoderma Gangrenosum Treated with Baricitinib: A Case Report
by: Han Seul Kim, et al.
Published: (2023)

Cure can be achieved by conversion to microwave ablation following atezolizumab-bevacizumab therapy in unresectable hepatocellular carcinoma
by: Rene John D. Febro, et al.
Published: (2024)

Letter regarding "Feasibility of additional radiotherapy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab"
by: Sun Hyun Bae, et al.
Published: (2023)

Hyperprogression in a Patient With Hepatocellular Cancer Treated With Atezolizumab and Bevacizumab: A Case Report and Review of Literature
by: Balraj Singh MD, et al.
Published: (2021)

Complete response in hepatocellular carcinoma with lymph node metastasis by combination therapy of atezolizumab and bevacizumab: a case report
by: Sang Youn Hwang, et al.
Published: (2021)

Favorable response of hepatocellular carcinoma with portal vein tumor thrombosis after radiotherapy combined with atezolizumab plus bevacizumab
by: Yong Tae Kim, et al.
Published: (2023)

A case of successful surgical treatment for peritoneal seeding of hepatocellular carcinoma after radiotherapy and atezolizumab plus bevacizumab combination treatment
by: Yuri Cho, et al.
Published: (2023)

Concurrent transarterial radioembolization and combination atezolizumab/bevacizumab treatment of infiltrative hepatocellular carcinoma with portal vein tumor thrombosis: a case report
by: Min Kyung Park, et al.
Published: (2022)

Advanced Therapeutic Gastrointestinal Endoscopy in Children - Today and Tomorrow
by: Zaheer Nabi, et al.
Published: (2018)

Submucosal endoscopy: the present and future
by: Zaheer Nabi, et al.
Published: (2023)

Cost-Effectiveness and Budget Impact Analyses of Selective Internal Radiation Therapy versus Atezolizumab Plus Bevacizumab from a German Statutory Health Insurance Perspective
by: Schwander B, et al.
Published: (2024)

A case of nearly complete response in hepatocellular carcinoma with disseminated lung metastasis by combination therapy of nivolumab and ipilimumab after treatment failure of atezolizumab plus bevacizumab
by: Hyung Jun Kim, et al.
Published: (2023)

Disease Control Achieved Using Atezolizumab + Bevacizumab in a Patient With Sarcomatoid Hepatocellular Carcinoma (SHCC), a Rare Variant Excluded From the IMbrave150 Trial
by: Maria G. Fencer MD, et al.
Published: (2022)

A case of urticarial vasculitis associated with atezolizumab
by: Jade N. Young, BS, et al.
Published: (2024)

Metronomic cyclophosphamide with bevacizumab provides disease stabilization in patients with advanced uterine cancer
by: Ioannis Alagkiozidis, et al.
Published: (2015)

Bevacizumab for glioblastoma
by: Narita Y
Published: (2015)

A model to optimize public health care and downstage breast cancer in limited-resource populations in southern Brazil. (Porto Alegre Breast Health Intervention Cohort)
by: Giacomazzi Juliana, et al.
Published: (2009)

Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1)
by: Benjamin Wu, et al.
Published: (2022)

Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2)
by: Solange Peters, et al.
Published: (2022)

A Rare Case Presentation of Vitiligo Associated With Atezolizumab
by: Kemnasom Nwanwene MD, et al.
Published: (2023)

Macular‐type cutaneous adverse reaction due to atezolizumab and pembrolizumab
by: Hitomi Sugino, et al.
Published: (2022)

Product review on the Anti-PD-L1 antibody atezolizumab
by: Neil J. Shah, et al.
Published: (2018)

Safety and Efficacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in the Downstaging of Intermediate-Stage Hepatocellular Carcinoma (HCC) in Patients With a Child-Pugh Score of 8-9
by: Roberto Minici, et al.
Published: (2021)

Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer
by: Lee Cheng Phua, et al.
Published: (2020)

Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab
by: Di Cao, et al.
Published: (2023)

Bevacizumab-Induced Geographic Tongue
by: Marta Martinez-Garcia, et al.
Published: (2021)

Monitoring antiangiogenesis of bevacizumab in zebrafish
by: Zhang J, et al.
Published: (2018)

Exposure-response analysis using time-to-event data for bevacizumab biosimilar SB8 and the reference bevacizumab
by: Suemin Park, et al.
Published: (2024)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
by: Qingli Cui, et al.
Published: (2022)

Linear IgA bullous dermatosis induced by atezolizumab: a case report
by: Seba Almutairi, et al.
Published: (2024)

Safety and efficacy of atezolizumab in the treatment of cancers: a systematic review and pooled-analysis
by: Tie Y, et al.
Published: (2019)

Atezolizumab-Induced Bell's Palsy in a Patient With Small Cell Lung Cancer
by: Asim Kichloo MD, et al.
Published: (2020)

POEM Is a Durable Treatment in Children and Adolescents With Achalasia Cardia
by: Zaheer Nabi, et al.
Published: (2022)